The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review ...
The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.
A systematic review highlights AI’s growing role in diagnosing and predicting vasculitis outcomes, with promising accuracy in Kawasaki disease. Learn more about these advancements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback